

# Marc-Eric Halatsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5736819/publications.pdf>

Version: 2024-02-01

29  
papers

923  
citations

471371

17  
h-index

477173

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1608  
citing authors

#	ARTICLE	IF	CITATIONS
1	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. <i>Cancers</i> , 2022, 14, 2563.	1.7	7
2	OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. <i>Cells</i> , 2021, 10, 1148.	1.8	2
3	A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab075.	0.4	26
4	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <i>Cancers</i> , 2021, 13, 4123.	1.7	9
5	In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 1241.	1.7	8
6	CTNI-04. RECURRENT GLIOBLASTOMA LONG-TERM SURVIVORS TREATED WITH CUSP9v3. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	0.6	1
7	Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old Woman. <i>World Neurosurgery</i> , 2020, 133, 413-415.	0.7	2
8	A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen. <i>Brain Sciences</i> , 2020, 10, 51.	1.1	7
9	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 287-301.	2.1	13
10	Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. <i>Scientific Reports</i> , 2018, 8, 5527.	1.6	15
11	Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen. <i>Brain Sciences</i> , 2018, 8, 203.	1.1	15
12	ACTR-44. PRELIMINARY RESULTS FROM THE NCT02770378 PROOF-OF-CONCEPT CLINICAL TRIAL ASSESSING THE SAFETY OF THE CUSP9v3 PROTOCOL COMBINED WITH METRONOMIC TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi21-vi21.	0.6	2
13	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. <i>Tumor Biology</i> , 2017, 39, 101042831769979.	0.8	45
14	Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells. <i>Tumor Biology</i> , 2017, 39, 101042831769222.	0.8	36
15	Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. <i>Neurochemical Research</i> , 2017, 42, 3382-3389.	1.6	29
16	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 495-514.	1.0	10
17	Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. <i>Oncotarget</i> , 2017, 8, 60727-60749.	0.8	27
18	Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 12791-12805.	0.8	35

#	ARTICLE	IF	CITATIONS
19	A paired comparison between glioblastoma stem cells and differentiated cells. International Journal of Cancer, 2016, 138, 1709-1718.	2.3	42
20	Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget, 2016, 7, 33512-33528.	0.8	47
21	A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. PLoS ONE, 2015, 10, e0131670.	1.1	37
22	RIST: A potent new combination therapy for glioblastoma. International Journal of Cancer, 2015, 136, E173-87.	2.3	42
23	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2015, 6, 14507-14521.	0.8	45
24	PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma. PLoS ONE, 2014, 9, e114583.	1.1	38
25	CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget, 2014, 5, 8052-8082.	0.8	99
26	Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 313-318.	0.9	35
27	Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. Molecular Cancer Therapeutics, 2013, 12, 1783-1795.	1.9	50
28	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530.	0.8	152
29	Matrix Metalloproteinase-2 and -9 in Glioblastoma: A Trio of Old Drugs—Captopril, Disulfiram and Nelfinavir—Are Inhibitors with Potential as Adjunctive Treatments in Glioblastoma. Archives of Medical Research, 2012, 43, 243-247.	1.5	47